Company Filing History:
Years Active: 2009-2012
Title: The Innovative Contributions of Xufang Zhang
Introduction
Xufang Zhang, an esteemed inventor located in Dresher, PA, has made significant contributions to the field of pharmaceutical science. With five patents to his name, his work primarily focuses on the development of CGRP receptor antagonists, which play a crucial role in the treatment of headache and migraine disorders.
Latest Patents
Xufang Zhang's latest inventions include two key patents related to tricyclic and bicyclic anilide spirolactam compounds. The first patent, entitled **Tricyclic Anilide Spirolactam CGRP Receptor Antagonists**, is directed to compounds that hold promise in preventing and treating various diseases associated with CGRP, such as headaches, migraines, and cluster headaches. This invention also encompasses pharmaceutical compositions that utilize these compounds in therapeutic applications. The second patent, **Bicyclic Anilide Spirolactam CGRP Receptor Antagonists**, similarly focuses on compounds useful as antagonists for CGRP receptors with applications in similar medical conditions. Both patents highlight his innovative approach to addressing significant medical challenges through targeted pharmaceutical solutions.
Career Highlights
Throughout his career, Xufang Zhang has had the opportunity to work with prominent companies in the pharmaceutical industry, notably Merck Sharp & Dohme Corporation and Merck & Company, Inc. His affiliations with these organizations have allowed him to contribute to meaningful advancements in drug development and therapeutic strategies.
Collaborations
Xufang Zhang has collaborated with talented colleagues, including Ian M. Bell and Steven N. Gallicchio. These partnerships have enriched his research endeavors and have facilitated the development of groundbreaking innovations in the pharmaceutical domain.
Conclusion
In summary, Xufang Zhang is a notable inventor whose work on CGRP receptor antagonists is paving the way for new treatment options for migraine and cluster headache sufferers. His patents reflect a commitment to innovative research and collaboration within the pharmaceutical industry, underscoring his significant contributions to medical science.